Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1998 5
1999 3
2001 3
2002 2
2005 3
2006 5
2007 7
2008 1
2009 5
2010 2
2011 2
2012 1
2016 1
2018 1
2019 2
2020 1
2021 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

41 results
Results by year
Filters applied: . Clear all
Page 1
Arylphthalazines as potent, and orally bioavailable inhibitors of VEGFR-2.
Duncton MA, Piatnitski Chekler EL, Katoch-Rouse R, Sherman D, Wong WC, Smith LM 2nd, Kawakami JK, Kiselyov AS, Milligan DL, Balagtas C, Hadari YR, Wang Y, Patel SN, Rolster RL, Tonra JR, Surguladze D, Mitelman S, Kussie P, Bohlen P, Doody JF. Duncton MA, et al. Among authors: tonra jr. Bioorg Med Chem. 2009 Jan 15;17(2):731-40. doi: 10.1016/j.bmc.2008.11.049. Epub 2008 Nov 24. Bioorg Med Chem. 2009. PMID: 19101155
Functional significance of VEGFR-2 on ovarian cancer cells.
Spannuth WA, Nick AM, Jennings NB, Armaiz-Pena GN, Mangala LS, Danes CG, Lin YG, Merritt WM, Thaker PH, Kamat AA, Han LY, Tonra JR, Coleman RL, Ellis LM, Sood AK. Spannuth WA, et al. Among authors: tonra jr. Int J Cancer. 2009 Mar 1;124(5):1045-53. doi: 10.1002/ijc.24028. Int J Cancer. 2009. PMID: 19058181 Free PMC article.
41 results